IN-VITRO STEPWISE SELECTION OF RESISTANCE TO QUINOLONES, BETA-LACTAMS AND AMIKACIN IN NOSOCOMIAL GRAM-NEGATIVE BACILLI

被引:20
|
作者
MICHEAHAMZEHPOUR, M [1 ]
KAHR, A [1 ]
PECHERE, JC [1 ]
机构
[1] UNIV GENEVA,CTR MED,DEPT GENET & MICROBIOL,CH-1211 GENEVA,SWITZERLAND
关键词
D O I
10.1007/BF01793574
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The ability of six antibiotics to produce resistance by stepwise selection on agar medium was assessed in 24 gram-negative rods. Escherichia coli was the strain least prone to selection of resistance, whereas Pseudomonas aeruginosa frequently developed resistance to all antibiotics. When used alone, ciprofloxacin, pefloxacin, amikacin, ceftazidime and cefpirome were associated with a comparable risk of acquired resistance (in 14 to 17 out of 24 strains); imipenem selected resistant strains in 10/24 isolates (5/18 in non-pseudomonas strains). The number of strains exhibiting cross resistance with structurally unrelated antibiotics was 11 after pefloxacin treatment, eight after exposure to ciprofloxacin, six after ceftazidime, and one after imipenem or cefpirome. The combination of ciprofloxacin with amikacin was less efficient in reducing acquisition of resistance than the combination of ciprofloxacin with a beta-lactam: ciprofloxacin plus cefpirome was especially potent in this respect.
引用
收藏
页码:S105 / S110
页数:6
相关论文
共 50 条
  • [41] SUSCEPTIBILITY TO AMIKACIN OF CLINICAL ISOLATES OF GRAM-NEGATIVE BACILLI FROM BRATISLAVA UNIVERSITY HOSPITALS AND MECHANISMS OF RESISTANCE
    MILOSOVIC, P
    KETTNER, M
    MACICKOVA, A
    JOURNAL OF CHEMOTHERAPY, 1993, 5 : 283 - 284
  • [42] ROLE OF BETA-LACTAMASES IN THE RESISTANCE OF GRAM-NEGATIVE BACILLI TO BETA-LACTAM ANTIBIOTICS
    ACAR, JF
    MINOZZI, C
    REVIEWS OF INFECTIOUS DISEASES, 1986, 8 : S482 - S486
  • [43] Beta-Lactams Dosing in Critically Ill Patients with Gram-Negative Bacterial Infections: A PK/PD Approach
    Maguigan, Kelly L.
    Al-Shaer, Mohammad H.
    Peloquin, Charles A.
    ANTIBIOTICS-BASEL, 2021, 10 (10):
  • [44] Efficacy and safety of colistin plus beta-lactams for bone and joint infection caused by fluoroquinolone-resistant gram-negative bacilli: a prospective multicenter study
    Mancheno-Losa, Mikel
    Murillo, Oscar
    Benavent, Eva
    Sorli, Luisa
    Riera, Melchor
    Cobo, Javier
    Benito, Natividad
    Morata, Laura
    Ribera, Alba
    Sobrino, Beatriz
    Fernandez-Sampedro, Marta
    Munez, Elena
    Bahamonde, Alberto
    Barbero, Jose Maria
    del Toro, M. Dolores
    Villa, Jenifer
    Rigo-Bonnin, Raul
    Luque, Sonia
    Garcia-Luque, Isabel
    Oliver, Antonio
    Esteban, Jaime
    Lora-Tamayo, Jaime
    INFECTION, 2025, 53 (01) : 359 - 372
  • [45] AMINOGLYCOSIDES PLUS BETA-LACTAMS AGAINST GRAM-NEGATIVE ORGANISMS - EVALUATION OF INVITRO SYNERGY AND CHEMICAL INTERACTIONS
    GIAMARELLOU, H
    AMERICAN JOURNAL OF MEDICINE, 1986, 80 (6B): : 126 - 137
  • [46] In vitro activity of fleroxacin against multiresistant gram-negative bacilli isolated from patients with nosocomial infections
    M. Araque
    E. Velazco
    Intensive Care Medicine, 1998, 24 : 839 - 844
  • [47] In vitro activity of fleroxacin against multiresistant gram-negative bacilli isolated from patients with nosocomial infections
    Araque, M
    Velazco, E
    INTENSIVE CARE MEDICINE, 1998, 24 (08) : 839 - 844
  • [48] PROBLEMS WITH DETECTION OF BETA-LACTAM RESISTANCE AMONG NONFASTIDIOUS GRAM-NEGATIVE BACILLI
    SANDERS, CC
    THOMSON, KS
    BRADFORD, PA
    INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 1993, 7 (02) : 411 - 424
  • [49] BETA LACTAMASE RESISTANCE OF NEWER CEPHALOSPORINS AND ANTIMICROBIAL EFFECTIVENESS AGAINST GRAM-NEGATIVE BACILLI
    FARRAR, WE
    ODELL, NM
    INFECTION, 1977, 5 (04) : 224 - 227
  • [50] Empirical fluoroquinolones versus broad-spectrum beta-lactams for Gram-negative bloodstream infections in the absence of antimicrobial resistance risk factors
    Al-Hasan, Majdi N.
    Gould, Alyssa P.
    Drennan, Chelsea
    Hill, Olivia
    Justo, Julie Ann
    Kohn, Joseph
    Bookstaver, P. Brandon
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2020, 22 : 87 - 93